KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Average (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Equity Average data on record, last reported at $30.4 million in Q3 2025.

  • For Q3 2025, Equity Average fell 52.65% year-over-year to $30.4 million; the TTM value through Sep 2025 reached $30.4 million, down 52.65%, while the annual FY2024 figure was $95.9 million, 61.47% down from the prior year.
  • Equity Average reached $30.4 million in Q3 2025 per NKTR's latest filing, up from -$5.2 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.0 billion in Q1 2021 and bottomed at -$5.2 million in Q2 2025.
  • Average Equity Average over 5 years is $360.0 million, with a median of $218.9 million recorded in 2023.
  • Peak YoY movement for Equity Average: fell 23.32% in 2021, then plummeted 105.07% in 2025.
  • A 5-year view of Equity Average shows it stood at $740.5 million in 2021, then plummeted by 47.41% to $389.4 million in 2022, then tumbled by 62.72% to $145.2 million in 2023, then crashed by 62.25% to $54.8 million in 2024, then crashed by 44.47% to $30.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $30.4 million in Q3 2025, -$5.2 million in Q2 2025, and $37.2 million in Q1 2025.